2026-10-23——
Pathos AI licenses Tempus neurological dataset under five-year, $55 million agreement
A short entry: a summary of the public record, checked against its sources, not yet read and analysed by Gianluca. How the register works
On 23 October 2026, Pathos AI announced a five-year, $55 million agreement to license a de-identified, longitudinal neurological-conditions dataset that Tempus AI will build from hundreds of thousands of patients. The announcement coincided with Pathos's $237 million Series E led by Bristol Myers Squibb.
What happened
- Announced 23 October 2026 by Pathos AI, with Tempus AI (NASDAQ: TEM) and Bristol Myers Squibb (NYSE: BMY).
- Pathos will license the dataset from Tempus under a five-year, $55 million agreement.
- Tempus will build a de-identified, longitudinal dataset from hundreds of thousands of patients with neurological conditions, applying infrastructure and expertise built in oncology.
- Pathos will apply its agentic AI platform, Pathos Foundry, to interrogate the dataset, generate and test hypotheses on disease biology, and inform clinical-trial design.
- BMS led Pathos's $237 million Series E financing at a post-money valuation of approximately $3 billion, gaining three-year exclusive rights to Pathos Foundry in neuroscience and non-exclusive access across its broader R&D portfolio.
Who is involved
Tempus AIListed · NASDAQ: TEM
Tempus does genome sequencing and precision medicine, including diagnostics, primarily for cancer patients.
Pathos AI
Pathos AI is an AI and technology company developing drugs.
Sources
- pathos.com — primary
- tempus.com — party background
- tikr.com — party background
- siliconangle.com — party background
- fiercebiotech.com — party background
Announced 2026-10-23